Budigalimab clinical trials
Also written ABBV-181.
How each study uses budigalimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2019 | 2 |
| 2020 | 3 |
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 4 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 15 · Other 0
AbbVie (12) · Trishula Therapeutics, Inc. (2) · Stemcentrx (1)
Often tested with
Tested in the same studies.
Livmoniplimab (6) · Revdofilimab (2) · Eltivutabart (2) · Docetaxel (1) · Paclitaxel (1) · Gemcitabine (1) · Modified FOLFOX6 Regimen (1) · Trosunilimab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5, 1 in phase 3
Studies that test budigalimab, phase 3 first.
- Jan 2027A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Phase 2/3 · AbbVie
- Nov 2026Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Phase 2 · AbbVie
- Mar 2027A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1 · AbbVie
- Mar 2027Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Phase 2 · AbbVie
- Jun 2027Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsPhase 1 · AbbVie
Studies
Open first, then newest update. How each study uses budigalimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 15
- A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382TerminatedPhase 2AbbVieNCT06032546Written as BudigalimabHow we know
- A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)TerminatedPhase 1AbbVieNCT06487559Written as BudigalimabHow we know
- Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingPhase 2/3AbbVieNCT06236438Written as BudigalimabHow we know
- A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2/3AbbVieNCT06109272Written as BudigalimabHow we know
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1AbbVieNCT03893955Written as ABBV-181How we know
- Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC PatientsCompletedPhase 2Trishula Therapeutics, Inc.NCT06119217Written as TTX-030, budigalimab, nab-paclitaxel and gemcitabineHow we know
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)Active, not recruitingPhase 2AbbVieNCT05822752Written as BudigalimabHow we know
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)Active, not recruitingPhase 2AbbVieNCT06632951Written as BudigalimabHow we know
- TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced CancersCompletedPhase 1Trishula Therapeutics, Inc.NCT04306900Written as TTX-030, budigalimab and mFOLFOX6How we know
- Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1AbbVieNCT03821935Written as BudigalimabHow we know
- A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1CompletedPhase 1AbbVieNCT04223804Written as ABBV-181How we know
- Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)CompletedPhase 1AbbVieNCT04799353Written as BudigalimabHow we know
- A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid TumorsCompletedPhase 1AbbVieNCT03000257Written as ABBV-181How we know
- A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell CarcinomaTerminatedPhase 1AbbVieNCT03818542Written as ABBV-181How we know
- Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian CancerTerminatedPhase 1StemcentrxNCT02539719Written as SC-003 in combination with ABBV-181How we know
Given beside what is tested · 14 — budigalimab is usual care or a partner of the new treatment
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingPhase 1/2AbbVieNCT06772623Written as BudigalimabHow we know
- A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous TumorsRecruitingPhase 1AbbVieNCT07241039Written as BudigalimabHow we know
- Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab AdizutecanRecruitingPhase 1AbbVieNCT05005403Written as BudigalimabHow we know
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal AdenocarcinomaActive, not recruitingPhase 2AbbVieNCT06628310Written as BudigalimabHow we know
- Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid TumorsActive, not recruitingPhase 1AbbVieNCT05599984Written as BudigalimabHow we know
- A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid TumorsActive, not recruitingPhase 1AbbVieNCT02988960Written as ABBV-181How we know
- A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid TumorsTerminatedPhase 1AbbVieNCT06158958Written as BudigalimabHow we know
- Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer MetastasisTerminatedPhase 1AbbVieNCT04807972Written as BudiglimabHow we know
- A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung CancerCompletedPhase 1AbbVieNCT03639194Written as BudigalimabHow we know
- A Study of ABT-165 in Subjects With Solid TumorsCompletedPhase 1AbbVieNCT01946074Written as ABBV-181How we know
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaCompletedPhase 1AbbVieNCT04196283Written as ABBV-181How we know
- A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid TumorsCompletedPhase 1AbbVieNCT03071757Written as ABBV-181How we know
- A Study of SC-006 and in Combination With ABBV-181 in Subjects With Advanced Colorectal CancerTerminatedPhase 1AbbVieNCT03035279Written as ABBV-181How we know
- SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial CancersTerminatedPhase 1AbbVieNCT03138408Written as ABBV-181How we know
What changed recently
From the registry's own updates since Oct 20, 2026.
Results posted1
Codes
What other systems call budigalimab · ClinicalTrials.gg INT001732
- MeSH (NLM) C000719868budigalimabOne source ClinicalTrials.gov
- UNII (FDA) 6VDO4TY3OOBUDIGALIMABOne source FDA
- NCI Thesaurus C137682BudigalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000719868 | budigalimab | One source ClinicalTrials.gov |
| UNII (FDA) | 6VDO4TY3OO | BUDIGALIMAB | One source FDA |
| NCI Thesaurus | C137682 | Budigalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.